Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | TK1 | P04183 | 4/20 | 0.60 |
| ▸ | TYMS | P04818 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727506 | 0.93 | POLB (0.62) | POLBTK1TYMS | |
| SCHEMBL4422933 | 0.91 | POLB (0.66) | POLBTK1TYMS | |
| SCHEMBL888318 | 0.90 | POLB (0.65) | POLBTK1TYMS | |
| SCHEMBL6753328 | 0.89 | POLB (0.61) | POLBTK1TYMS | |
| SCHEMBL887852 | 0.89 | TK1 (0.69) | POLBTK1TYMS | |
| SCHEMBL16359946 | 0.89 | TK1 (0.69) | POLBTK1TYMS | |
| SCHEMBL5506140 | 0.89 | POLB (0.60) | POLBTK1TYMS | |
| SCHEMBL4727317 | 0.89 | POLB (0.60) | POLBTK1TYMS | |
| SCHEMBL5367837 | 0.89 | POLB (0.60) | POLBTK1TYMS | |
| SCHEMBL5163079 | 0.89 | POLB (0.60) | POLBTK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 820 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4745238-A1 | OLIGONUCLEOTIDE TARGETING ANGIOTENSINOGEN AND USE THEREOF | Anlong Biopharmaceutical Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12577564-B2 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12534731-B2 | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | claimed |
| EP-4677094-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | Basecure Therapeutics LLC (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2025264548-A2 | MODIFIED POLYNUCLEIC ACID MOLECULES TARGETING AGT AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4665852-A1 | MODIFIED DOUBLE STRANDED RNA AGENTS | Basecure Therapeutics (HK) | 2025-12-24 | — | — | EP | claimed |
| WO-2018098117-A1 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-31 | — | — | WO | claimed |
| EP-3283631-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-3221451-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| US-20170260527-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2017-09-14 | — | — | US | claimed |
| WO-2016209862-A1 | GLUCOKINASE (GCK) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-29 | — | — | WO | claimed |
| WO-2016168286-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | WO | claimed |
| WO-2016081444-A9 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-21 | — | — | WO | claimed |
| WO-2016081444-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | claimed |
| US-20130280706-A1 | Compositions and Methods for Quantifying a Nucleic Acid Sequence in a Sample | ENVIROLOGIX INC. (US) | 2013-10-24 | — | — | US | claimed |
| WO-2012021493-A2 | COMPOSITIONS AND METHODS FOR QUANTIFYING A NUCLEIC ACID SEQUENCE IN A SAMPLE | ENVIROLOGIX INC. (US) | 2012-02-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534731-B2 | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof | ADRA2A, ADRB2, ADRA2B | POLB 469/4885TK1 2488/4885TYMS 2402/4885 |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | TMPRSS2, TMPRSS11D, TMPRSS4 | POLB 1821/4885TK1 3149/4885TYMS 836/4885 |
| US-12577564-B2 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | SREBF1, SREBF2, ATF4 | POLB 2465/4885TK1 2733/4885TYMS 2000/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | POLB 770/4885TK1 1049/4885TYMS 885/4885 |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ATXN2, ATXN2L, ATXN10 | POLB 448/4885TK1 2254/4885TYMS 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.